entecavir and Lymphangioleiomyomatosis

entecavir has been researched along with Lymphangioleiomyomatosis* in 1 studies

Other Studies

1 other study(ies) available for entecavir and Lymphangioleiomyomatosis

ArticleYear
Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier.
    Internal medicine (Tokyo, Japan), 2019, Feb-15, Volume: 58, Issue:4

    A 34-year-old woman experiencing shortness of breath was referred to our hospital. The patient was diagnosed with sporadic lymphangioleiomyomatosis based on the observation of bilateral diffuse multiple thin-walled cysts on computed tomography of the chest, chylous effusion, elevated serum vascular endothelial growth factor-D levels and transbronchial biopsy findings. This patient was a hepatitis B virus (HBV) carrier. Treatment with 1 mg daily of sirolimus was started after HBV DNA was brought below the cut-off level using entecavir. Sirolimus was effective, as the chylous effusion resolved completely and the dyspnea improved. The sirolimus dosage was increased to 2 mg daily without causing HBV reactivation.

    Topics: Adult; Antiviral Agents; Female; Guanine; Hepatitis B; Hepatitis B virus; Humans; Lymphangioleiomyomatosis; Sirolimus; Tomography, X-Ray Computed; Treatment Outcome

2019